iX Biopharma's (SGX:42C) net loss attributable to equity holders widened 196% to SG$5.0 million during the fiscal fourth quarter ended June 30 from SG$1.7 million a year earlier.
Loss per share came in at SG$0.0048 compared with SG$0.0019 in the year-ago period, according to a Friday filing with the Singapore Exchange.
Revenue fell 7% year over year to SG$2.1 million from SG$2.2 million.
Shares of the healthcare provider were down nearly 9% Monday morning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.